27/03/2008 (Agence Europe) - The European Medicines Agency (EMEA) recommends that Velcade (bortezomib) should not be used in patients with certain severe pulmonary or heart problems (acute diffuse infiltrative pulmonary and pericardial disease). In other patients presenting multiple myeloma, the benefits of Velcade remain greater than the risks entailed, as a last resort, a 20 March press release states. (O.J.)